These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31902674)

  • 1. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
    Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
    FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.
    Zhang D; Hu Q; Liu X; Ji Y; Chao HP; Liu Y; Tracz A; Kirk J; Buonamici S; Zhu P; Wang J; Liu S; Tang DG
    Nat Commun; 2020 Apr; 11(1):2089. PubMed ID: 32350277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
    Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer.
    Sáez-Martínez P; Jiménez-Vacas JM; León-González AJ; Herrero-Aguayo V; Montero Hidalgo AJ; Gómez-Gómez E; Sánchez-Sánchez R; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
    Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
    Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
    Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
    Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
    Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
    Jones DZ; Schmidt ML; Suman S; Hobbing KR; Barve SS; Gobejishvili L; Brock G; Klinge CM; Rai SN; Park J; Clark GJ; Agarwal R; Kidd LR
    BMC Cancer; 2018 Apr; 18(1):421. PubMed ID: 29653561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
    Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
    Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis.
    Kiliccioglu I; Bilen CY; Sozen S; Konac E
    Gene; 2021 Mar; 772():145377. PubMed ID: 33359129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.